3 Biotech Stocks With Big News Coming in NASH

After Gilead Sciences (NASDAQ:GILD) transformed hepatitis C treatment with drugs offering functional cures, biopharmaceutical research has turned its attention toward another significant cause of liver transplant: nonalcoholic steatohepatitis (NASH).